NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio ® (avelumab), a ...
Cancer Res (2025) 85 (8_Supplement_2): ND11.
Mol Cancer Ther (2023) 22 (12_Supplement): A023. Conclusions:Lunresertib and the WEE1 inhibitor Debio-0123 elicit strong synergistic activity in preclinical models of CCNE1-overexpressoin due to rapid ...
Cancer Res (2025) 85 (8_Supplement_1): 372.
Cancer Res (2023) 83 (7_Supplement): 1142.
Abstract. A key barrier to effective immunotherapy for cancer is the immunosuppressive tumor microenvironment (TME) characterized by infiltrating regulatory T cells (Tregs) and myeloid-derived ...
Background: KRAS is a key mediator of the RAS/MAPK signaling cascade and promotes cellular growth and proliferation. It is the most frequently mutated oncogene in cancer, and KRAS G12C mutations occur ...
Abstract:. In updated phase I clinical trial results, patients treated with zoldonrasib, a KRASG12D-selective inhibitor under study in non–small cell lung cancer, showed an objective response rate of ...
Cancer Res (2026) 86 (2_Supplement): B076.
Introduction: EBV-associated nasopharyngeal carcinoma (NPC) is a distinct type of head and neck cancer that is prevalence in southern China and Southeast Asia. While radiotherapy or concurrent ...
Cancer Res (2026) 86 (5_Supplement_2): A010.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results